The field of optometry is advancing fast. New technologies and medical products are being developed at a rapid pace. One product that has fairly recently joined the list of treatments available for eye care is Xiidra. This product has proved to be quite effective in treating both the symptoms and signs of dry eye.
The clinical director at Eye & Vision notes that despite all the information available about dry eye, there has not been a new product that accomplishes what this medication is doing. He laments though that while the amount of knowledge has grown tremendously, the amount of treatment options has not.
Just like with any new prescription, issues often bound that need clarification. For instance, are there any possible side effects, and if so, what are these side effects? What is the correct dosage of the prescription? These and other vital questions are important to the optometrist.
In response to some of these issues, Mike Brujic notes that some patients saw results after only two weeks of using this drops. Educating the patient that the medication treats chronic a condition requiring a medical prescription is crucial. At the clinical trial stage some patients experienced slight eye irritation and altered taste but Brunjic advises such patients to stay on course to avoid drop-out.
Since this medication is still new caution needs to be taken. However, though some patients report some side effects, nothing serious has been noted to date. In short, there is a lot of information about this prescription that needs to find its way to the optometrists in the field.
Once this medication is approved in the different countries, the information about its use, benefits, dosage and side effects will be passed formally to the practitioners in the field. The accumulated knowledge and experience of the physicians who have prescribed this medication will certainly come in handy in creating awareness among the rest of thee optometrist community.
According to Robert Demsey, Vice president of opthalmics at Shire, plans are already underway to have this medication approved in different parts of the world. What does this portend to practicing optometricians in those countries.
The only official mode of keeping optometrists updated with these new developments is through optometry continuing education courses. Optometrists can opt to get this information through online CE courses or through studying at conventional institutions.
Depending on the mode of study one chooses one will get the benefits and challenges of either. Online study is flexible and affordable. An optometrist will study at his or her own speed and from anywhere on the globe. However, for those who prefer the feel of a conventional classroom, they can opt for the brick and motor institutions instead. With this option, however, optometrists need to be ready to follow a strict timetable and attend class in person.
Another challenge of the latter option is its cost; in most cases it’s more costly than the online programs. With these available avenues of staying abreast with developments in optometry medication and treatment, there’s no reason why ones should not regularly pursue approved optometry CE.